Clinical study protocol template
PRO patient reported outcome PT prothrombin time QM quality management QOL quality of life QTcF Fridericia QT correction formula RAST radioallergosorbent test SABA short-acting -agonist SAE(s) serious adverse event(s) SAF safety analysis set sCr serum creatinine SCR screening SD standard deviation SJS Stevens-Johnson syndrome SoC standard of care
Download Clinical study protocol template
Information
Domain:
Source:
Link to this page:
Documents from same domain
New antibiotic treatment options for uncomplicated ...
clinicaltrials.govtreatment options for gonorrhoea and only a few new drugs in the development pipeline, it is important to test existing antibiotics for their efficacy in gonorrhoea treatment. Objective : This project aims to identify new treatment modalities for uncomplicated gonorrhoea using
A PROSPECTIVE MULTI CENTER RANDOMIZED CONTROLLED …
clinicaltrials.govconjunction with Ceramic on Ceramic and Taperloc Complete Microplastyarticulation stem in primary total hip arthroplasty compared to patients who received the Exceed ABT Acetabular system with the same combination.
Title: A Phase 1, Randomized, Double-Blind, Placebo ...
clinicaltrials.govA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects Phase 1 TAK-653 Escalating Single and Multiple Dose Study in Healthy Subjects Sponsor: Takeda Development Centre Europe Ltd. 61 Aldwych London, WC2B 4AE United Kingdom
Statistical Analysis Plan (SAP) - ClinicalTrials.gov
clinicaltrials.govstatistical analysis. The subsections below will describe analyses in addition to the descriptive statistics. 6.1 Primary outcome The primary analysis will compare intervention groups (water supplementation vs control treatment) on their mean change in fasting plasma glucose between baseline and 12 months using a linear mixed model.
A Phase II, Randomized, Double -blind, Placebo -controlled ...
clinicaltrials.gov• International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated Guideline. • All applicable laws and regulations, including, without limitation, data privacy laws and regulations. • Regulatory requirements for reporting serious …
Clinical Study Report (CSR) Template (Drug and Device)
clinicaltrials.govATC Anatomical Therapeutic Chemical CFB change from baseline DHA dapsone hydroxylamine eCRF electronic case report form IGA Investigator’s Global Assessment MedDRA Medication Dictionary for Regulatory Activities mITT modified intent-to-treat NAD N-acetyl dapsone PK pharmacokinetic ...
Research Proposal - ClinicalTrials.gov
clinicaltrials.govas fecal microbiota transplantation (FMT). 4. Procedures Tissue samples will be obtained from consenting patients at (SDMCUT), or other relevant facilities (see section 6.i below), in accordance with protocols approved by the University of Texas Institutional Review Board (UTIRB). Patients who meet eligibility criteria will have their
Novartis CSR template
clinicaltrials.gov9.1 Study design Figure 9-1 Study design BID: twice a day, QD: once a day. This was a multicenter, randomized, double-masked, two-arm, placebo-controlled, parallel-group study in patients with normal tension glaucoma who were insufficiently controlled on travoprost 0.004% (Travatan) monotherapy. Approximately 200 patients were planned to be
DETAILED STATISTICAL ANALYSIS PLAN (SAP)
clinicaltrials.govStatistical principles : 4.1. Multiplicity : The diagnostic and prognostic basic stud y and each sub -study consist of one primary outcome and one or more secondary, exploratory outcomes. We will encounter multiplicity issues due to the multiple
Title: TWILIGHT Study - Ticagrelor With Aspirin or Alone ...
clinicaltrials.govPrior stroke Dialysis-dependent renal failure Active bleeding or extreme-risk for major bleeding (e.g. acute ... Life expectancy < 1 year ... 7.3.4 Adverse Events based on signs and symptoms ...
Related documents
QOLに関するPatient Reported Outcomeの評価
archive.jsco.or.jpQOLに関するPatient Reported Outcomeの評価 1．はじめに がん治療の評価には生存期間や抗腫瘍効果といった 客観的な指標が主に用いられる。それら客観的評価に 加えて患者の視点にたった指標であるQuality of Life （QOL） も評価される臨床試験が多くなっている。延命
The Communicative Participation Item Bank – General Short …
ancds.memberclicks.net– “QOL is a critical outcome following any intervention…the initial evaluation focuses on the patient's lifestyle and activities of importance to them ….” [L12] – ... Parkinson’s disease Self‐reported speech ...
Clinical Practice Guidelines
www.orthopt.orgEXAMINATION – OUTCOME MEASURES: ACTIVITY LIMITATIONS AND SELF-REPORTED MEASURES B Clinicians should use the International Knee Documentation Committee 2000 Subjective Knee Evaluation Form (IKDC 2000) or Knee injury and Osteoarthritis Outcome Score (KOOS), and may use the Lysholm scale, as validated patient-reported outcome